ClinicalTrials.gg
CompletedNCT02828020ACHIEVE IUpdated Jan 3, 2019Results posted

Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine

A Phase 3 interventional study of Ubrogepant and Placebo-matching Ubrogepant in Migraine, With or Without Aura, sponsored by Allergan. Completed at 90 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-01-03.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,672
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing ubrogepant in Migraine Disorders — 2 open to participants now, 4 under way, 3 of them phase 3. ubrogepant · Migraine Disorders.

Enrollment
2nd of 14
1,672 · median 507
Started
2016
with 2 others
Phase 3
7 of 14
2 open now
Registered
3rd of 14
by date
Lead sponsor
6 of 14
Allergan

Among the 14 studies testing ubrogepant in Migraine Disorders, this one is the 2nd largest by enrollment, is one of 3 that started in 2016, is one of 7 in phase 3, and was the 3rd registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

2 of the 14 studies testing ubrogepant in Migraine Disorders are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About ubrogepant

ubrogepant: first FDA approval 2019 (UBRELVY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing ubrogepant in Migraine Disorders, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (50 and 100 mg) compared to placebo for the acute treatment of a single migraine attack.

03

Conditions studied

  • Migraine, With or Without Aura

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least a 1-year history of migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd edition, beta version
  • Migraine onset before age 50
  • History of migraines typically lasting between 4 and 72 hours if untreated or treated unsuccessfully and migraine episodes are separated by at least 48 hours of headache pain freedom
  • History of 2 to 8 migraine attacks per month with moderate to severe headache pain in each of the previous 3 months.

Exclusion criteria

Exclusion Criteria:

  • Difficulty distinguishing migraine headache from other headaches
  • Has taken medication for acute treatment of headache (including acetaminophen, nonsteroidal anti-inflammatory drugs [NSAIDs], triptans, ergotamine, opioids, or combination analgesics) on 10 or more days per month in the previous 3 months
  • Has a history of migraine aura with diplopia or impairment of level of consciousness, hemiplegic migraine, or retinal migraine
  • Has a current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy
  • Required hospital treatment of a migraine attack 3 or more times in the previous 6 months
  • Has a chronic non-headache pain condition requiring daily pain medication
  • Has a history of in the prior 5 years, except for adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer
  • Has a history of any prior gastrointestinal conditions (eg, diarrhea syndromes, inflammatory bowel disease) that may affect the absorption or metabolism of product; participants with prior gastric bariatric interventions which have been reversed are not excluded
  • Has a history of hepatitis within previous 6 months.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,672 participants (actual)

Study arms

  • Experimental
    Ubrogepant 50 mg

    1 ubrogepant 50 mg tablet and 1 placebo-matching ubrogepant 50 mg tablet, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, 2 placebo-matching ubrogepant tablets or rescue medication, orally 2 to 48 hours after initial treatment.

    Drug: Ubrogepant · Drug: Placebo-matching Ubrogepant

  • Experimental
    Ubrogepant 100 mg

    2 Ubrogepant 50 mg tablets, orally for treatment of a qualifying migraine attack. Participants had the option to take a second dose, 2 placebo-matching ubrogepant tablets or rescue medication, orally 2 to 48 hours after initial treatment.

    Drug: Ubrogepant · Drug: Placebo-matching Ubrogepant

  • Placebo comparator
    Placebo

    2 placebo-matching ubrogepant 50 mg tablets, orally for treatment of a qualifying migraine attack. Participants had the option to take 2-placebo-matching ubrogepant tablets or rescue medication, orally 2 to 48 hours after initial treatment.

    Drug: Placebo-matching Ubrogepant

Interventions

  • 50 mg ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.

  • DrugPlacebo-matching Ubrogepant

    Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose

    Pain freedom was defined as a reduction in headache severity from moderate/severe at baseline to no pain at 2 hours after the initial dose. Participants were provided with an electronic diary (eDiary) to rate headache severity on a scale from no pain to severe pain. Number analyzed is the number of participants with non-missing postdose pain severity assessment at or before 2 hours after initial dose.

    Time frame: Baseline (Predose) to 2 hours after initial dose

  2. Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose

    The most bothersome migraine-associated symptom was the symptom (photophobia, phonophobia or nausea) present at pre-dose baseline identified by the participant to be 'most bothersome'. Participants were provided with an eDiary to record absence or presence of migraine-associated symptoms. Number analyzed is the number of participants with non-missing postdose most bothersome migraine-associated symptoms.

    Time frame: Baseline (Predose) to 2 hours after initial dose

Secondary outcomes

  1. Percentage of Participants With Pain Relief at 2 Hours After the Initial Dose

    Pain relief was defined as a reduction of a moderate/severe migraine headache to a mild headache or to no headache. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Number analyzed is the number of participants with non-missing pain severity assessment at or before 2 hours after initial dose.

    Time frame: Baseline (Predose) to 2 hours after initial dose

  2. Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours After Initial Dose

    Sustained pain relief was defined as a pain relief at 2 hours with no administration of either rescue medication or the second dose of study drug, and with no occurrence thereafter of a moderate/severe headache up to 24 hours after dosing with study drug. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Determinable cases: participants for whom sustained pain relief from 2 to 24 hours status can be determined based on the observed headache severity at scheduled time points, use of rescue medication or optional second dose between 2 and 24 hours, and the answer to the headache recurrence question at 24 hours. Number analyzed is the number of participants with determinable sustained pain relief from 2 to 24 hours after initial dose.

    Time frame: 2 to 24 hours after initial dose

  3. Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours After Initial Dose

    Sustained pain freedom was defined as a pain freedom at 2 hours with no administration of either rescue medication or the second dose of study drug, and with no occurrence thereafter of a mild/moderate/severe headache up to 24 hours after dosing with study drug. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Determinable cases: participants for whom sustained pain relief from 2 to 24 hours status can be determined based on the observed headache severity at scheduled time points, use of rescue medication or optional second dose between 2 and 24 hours, and the answer to the headache recurrence question at 24 hours. Number analyzed is the number of participants with determinable sustained pain freedom from 2 to 24 hours after initial dose.

    Time frame: 2 to 24 hours after initial dose

  4. Percentage of Participants With the Absence of Photophobia at 2 Hours After the Initial Dose

    Photophobia was defined as sensitivity to light, a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence photophobia. Number analyzed is the number of participants with non-missing postdose photophobia assessment at or before 2 hours after initial dose.

    Time frame: 2 hours after initial dose

  5. Percentage of Participants With the Absence of Phonophobia at 2 Hours After the Initial Dose

    Phonophobia was defined as sensitivity to sound, a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence of phonophobia. Number analyzed is the number of participants with non-missing postdose phonophobia assessment at or before 2 hours after initial dose.

    Time frame: 2 hours after initial dose

  6. Percentage of Participants With Absence of Nausea at 2 Hours After the Initial Dose

    Nausea was a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence of nausea. Number analyzed is the number of participants with non-missing postdose nausea assessment at or before 2 hours after initial dose.

    Time frame: 2 hours after initial dose

07

Results

Posted Jan 3, 2019

Participant flow

Treatment Period
Participant flow — Treatment Period
MilestonePlaceboUbrogepant 50 mgUbrogepant 100 mg
Started559556557
Safety population: received study drug485466485
Completed479457479
Not completed809978
Withdrew: Adverse event311
Withdrew: Withdrawal of consent10149
Withdrew: Lost to follow-up212418
Withdrew: Lack of qualifying event445343
Withdrew: Pregnancy020
Withdrew: Protocol violation247
Withdrew: Other miscellaneous reasons010
Safety Follow-up Period
Participant flow — Safety Follow-up Period
MilestonePlaceboUbrogepant 50 mgUbrogepant 100 mg
Started480458480
Completed460440461
Not completed201819
Withdrew: Withdrawal of consent1087
Withdrew: Lost to follow-up9811
Withdrew: Protocol violation021
Withdrew: Other miscellaneous reasons100

Outcome measures

PrimaryPercentage of Participants With Pain Freedom at 2 Hours After Initial Dose

Pain freedom was defined as a reduction in headache severity from moderate/severe at baseline to no pain at 2 hours after the initial dose. Participants were provided with an electronic diary (eDiary) to rate headache severity on a scale from no pain to severe pain. Number analyzed is the number of participants with non-missing postdose pain severity assessment at or before 2 hours after initial dose.

Time frame:
Baseline (Predose) to 2 hours after initial dose
Reported as:
Number · percentage of participants
Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose
percentage of participantsPlaceboUbrogepant 50 mgUbrogepant 100 mg
Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose11.819.221.2
Statistical analysis
  • Placebo vs Ubrogepant 50 mg · Regression, Logistic · p = 0.0023 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.83 · 95% CI 1.25 to 2.66Treatment group, historical triptan response, medication use for migraine prevention, baseline headache severity were explanatory variables in model.
  • Placebo vs Ubrogepant 100 mg · Regression, Logistic · p = 0.0003 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 2.04 · 95% CI 1.41 to 2.95Treatment group, historical triptan response, medication use for migraine prevention, baseline headache severity were explanatory variables in model.
PrimaryPercentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose

The most bothersome migraine-associated symptom was the symptom (photophobia, phonophobia or nausea) present at pre-dose baseline identified by the participant to be 'most bothersome'. Participants were provided with an eDiary to record absence or presence of migraine-associated symptoms. Number analyzed is the number of participants with non-missing postdose most bothersome migraine-associated symptoms.

Time frame:
Baseline (Predose) to 2 hours after initial dose
Reported as:
Number · percentage of participants
Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose
percentage of participantsPlaceboUbrogepant 50 mgUbrogepant 100 mg
Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose27.838.637.7
Statistical analysis
  • Placebo vs Ubrogepant 50 mg · Regression, Logistic · p = 0.0023 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.70 · 95% CI 1.27 to 2.28Treatment group, historical triptan response, migraine prevention medication, baseline headache severity, underlying symptom as explanatory variables.
  • Placebo vs Ubrogepant 100 mg · Regression, Logistic · p = 0.0023 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.63 · 95% CI 1.22 to 2.17Treatment group, historical triptan response, migraine prevention medication, baseline headache severity, underlying symptom as explanatory variables.
SecondaryPercentage of Participants With Pain Relief at 2 Hours After the Initial Dose

Pain relief was defined as a reduction of a moderate/severe migraine headache to a mild headache or to no headache. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Number analyzed is the number of participants with non-missing pain severity assessment at or before 2 hours after initial dose.

Time frame:
Baseline (Predose) to 2 hours after initial dose
Reported as:
Number · percentage of participants
Percentage of Participants With Pain Relief at 2 Hours After the Initial Dose
percentage of participantsPlaceboUbrogepant 50 mgUbrogepant 100 mg
Percentage of Participants With Pain Relief at 2 Hours After the Initial Dose49.160.761.4
Statistical analysis
  • Placebo vs Ubrogepant 50 mg · Regression, Logistic · p = 0.0023 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.69 · 95% CI 1.28 to 2.23Treatment group, historical triptan response, medication use for migraine prevention, baseline headache severity were explanatory variables in model.
  • Placebo vs Ubrogepant 100 mg · Regression, Logistic · p = 0.0023 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.69 · 95% CI 1.28 to 2.21Treatment group, historical triptan response, medication use for migraine prevention, baseline headache severity were explanatory variables in model.
SecondaryPercentage of Participants With Sustained Pain Relief From 2 to 24 Hours After Initial Dose

Sustained pain relief was defined as a pain relief at 2 hours with no administration of either rescue medication or the second dose of study drug, and with no occurrence thereafter of a moderate/severe headache up to 24 hours after dosing with study drug. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Determinable cases: participants for whom sustained pain relief from 2 to 24 hours status can be determined based on the observed headache severity at scheduled time points, use of rescue medication or optional second dose between 2 and 24 hours, and the answer to the headache recurrence question at 24 hours. Number analyzed is the number of participants with determinable sustained pain relief from 2 to 24 hours after initial dose.

Time frame:
2 to 24 hours after initial dose
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours After Initial Dose
percentage of participantsPlaceboUbrogepant 50 mgUbrogepant 100 mg
Percentage of Participants With Sustained Pain Relief From 2 to 24 Hours After Initial Dose20.836.338.0
Statistical analysis
  • Placebo vs Ubrogepant 50 mg · Regression, Logistic · p = 0.0023 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 2.25 · 95% CI 1.65 to 3.07Treatment group, historical triptan response, medication use for migraine prevention, baseline headache severity were explanatory variables in model.
  • Placebo vs Ubrogepant 100 mg · Regression, Logistic · p = 0.0023 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 2.39 · 95% CI 1.77 to 3.24Treatment group, historical triptan response, medication use for migraine prevention, baseline headache severity were explanatory variables in model.
SecondaryPercentage of Participants With Sustained Pain Freedom From 2 to 24 Hours After Initial Dose

Sustained pain freedom was defined as a pain freedom at 2 hours with no administration of either rescue medication or the second dose of study drug, and with no occurrence thereafter of a mild/moderate/severe headache up to 24 hours after dosing with study drug. Participants were provided with an eDiary to rate headache severity on a scale from no pain to severe pain. Determinable cases: participants for whom sustained pain relief from 2 to 24 hours status can be determined based on the observed headache severity at scheduled time points, use of rescue medication or optional second dose between 2 and 24 hours, and the answer to the headache recurrence question at 24 hours. Number analyzed is the number of participants with determinable sustained pain freedom from 2 to 24 hours after initial dose.

Time frame:
2 to 24 hours after initial dose
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours After Initial Dose
percentage of participantsPlaceboUbrogepant 50 mgUbrogepant 100 mg
Percentage of Participants With Sustained Pain Freedom From 2 to 24 Hours After Initial Dose8.612.715.4
Statistical analysis
  • Placebo vs Ubrogepant 50 mg · Regression, Logistic · p = 0.0577 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.57 · 95% CI 1.01 to 2.44Treatment group, historical triptan response, medication use for migraine prevention, baseline headache severity were explanatory variables in model.
  • Placebo vs Ubrogepant 100 mg · Regression, Logistic · p = 0.0037 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.95 · 95% CI 1.28 to 2.97Treatment group, historical triptan response, medication use for migraine prevention, baseline headache severity were explanatory variables in model.
SecondaryPercentage of Participants With the Absence of Photophobia at 2 Hours After the Initial Dose

Photophobia was defined as sensitivity to light, a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence photophobia. Number analyzed is the number of participants with non-missing postdose photophobia assessment at or before 2 hours after initial dose.

Time frame:
2 hours after initial dose
Reported as:
Number · percentage of participants
Percentage of Participants With the Absence of Photophobia at 2 Hours After the Initial Dose
percentage of participantsPlaceboUbrogepant 50 mgUbrogepant 100 mg
Percentage of Participants With the Absence of Photophobia at 2 Hours After the Initial Dose31.440.745.8
Statistical analysis
  • Placebo vs Ubrogepant 50 mg · Regression, Logistic · p = 0.0577 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.63 · 95% CI 1.22 to 2.19Treatment group, historical triptan response, migraine prevention medication, baseline headache severity, photophobia were explanatory variables.
  • Placebo vs Ubrogepant 100 mg · Regression, Logistic · p = 0.0037 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.81 · 95% CI 1.36 to 2.42Treatment group, historical triptan response, migraine prevention medication, baseline headache severity, photophobia were explanatory variables.
SecondaryPercentage of Participants With the Absence of Phonophobia at 2 Hours After the Initial Dose

Phonophobia was defined as sensitivity to sound, a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence of phonophobia. Number analyzed is the number of participants with non-missing postdose phonophobia assessment at or before 2 hours after initial dose.

Time frame:
2 hours after initial dose
Reported as:
Number · percentage of participants
Percentage of Participants With the Absence of Phonophobia at 2 Hours After the Initial Dose
percentage of participantsPlaceboUbrogepant 50 mgUbrogepant 100 mg
Percentage of Participants With the Absence of Phonophobia at 2 Hours After the Initial Dose47.157.954.5
Statistical analysis
  • Placebo vs Ubrogepant 50 mg · Regression, Logistic · p = 0.0577 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.56 · 95% CI 1.16 to 2.09Treatment group, historical triptan response, migraine prevention medication, baseline headache severity, phonophobia were explanatory variables.
  • Placebo vs Ubrogepant 100 mg · Regression, Logistic · p = 0.0577 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.47 · 95% CI 1.10 to 1.95Treatment group, historical triptan response, migraine prevention medication, baseline headache severity, phonophobia were explanatory variables.
SecondaryPercentage of Participants With Absence of Nausea at 2 Hours After the Initial Dose

Nausea was a migraine-associated symptom. Participants were provided with an eDiary to record absence or presence of nausea. Number analyzed is the number of participants with non-missing postdose nausea assessment at or before 2 hours after initial dose.

Time frame:
2 hours after initial dose
Reported as:
Number · percentage of participants
Percentage of Participants With Absence of Nausea at 2 Hours After the Initial Dose
percentage of participantsPlaceboUbrogepant 50 mgUbrogepant 100 mg
Percentage of Participants With Absence of Nausea at 2 Hours After the Initial Dose62.370.269.2
Statistical analysis
  • Placebo vs Ubrogepant 50 mg · Regression, Logistic · p = 0.0962 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.31 · 95% CI 0.96 to 1.79Treatment group, historical triptan response, migraine prevention medication, baseline headache severity, nausea were explanatory variables.
  • Placebo vs Ubrogepant 100 mg · Regression, Logistic · p = 0.0962 (P-value was adjusted for multiple comparisons across primary and secondary endpoints and multiple doses.) · Odds ratio (or): 1.35 · 95% CI 1.00 to 1.83Treatment group, historical triptan response, migraine prevention medication, baseline headache severity, nausea were explanatory variables.

Adverse events

Collected over From first dose through 30 days after the last dose of study drug (approximately 30 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/485 (0%)0/485 (0%)0/485 (0%)
Ubrogepant 50 mg0/466 (0%)3/466 (0.6%)0/466 (0%)
Ubrogepant 100 mg0/485 (0%)2/485 (0.4%)0/485 (0%)
Most frequent serious events
Most frequent serious events
EventPlaceboUbrogepant 50 mgUbrogepant 100 mg
AppendicitisInfections and infestations0/4851/4661/485
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/4851/4660/485
Pericardial effusionCardiac disorders0/4851/4660/485
SeizureNervous system disorders0/4850/4661/485

Baseline characteristics

Intent-to-Treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboUbrogepant 50 mgUbrogepant 100 mgTotal
Mean41.1 ± 11.940.2 ± 12.040.7 ± 12.440.7 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboUbrogepant 50 mgUbrogepant 100 mgTotal
Female4914934791463
Male686378209
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboUbrogepant 50 mgUbrogepant 100 mgTotal
White4714594471377
Black or African American657788230
Asian109827
American Indian or Alaska Native33511
Native Hawaiian/Other Pacific Islander3159
Multiple77418
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboUbrogepant 50 mgUbrogepant 100 mgTotal
Hispanic or Latino606766193
Not Hispanic or Latino4994894911479
08

Study locations

90 sites
  • Clinical Research Advantage, Inc./Desert Clinical Research, LLC.
    Mesa, Arizona 85213, United States
  • Xenoscience, Inc.
    Phoenix, Arizona 85004, United States
  • Clinical Research Advantage, Inc./Orange Grove Family Practice
    Tucson, Arizona 85741, United States
  • Principals Research Group, Inc.
    Hot Springs, Arkansas 71901, United States
  • KLR Business Group, Inc. dba Arkansas Clinical Research
    Little Rock, Arkansas 72205, United States
  • The Research Center of Southern California, LLC
    Carlsbad, California 92011, United States
  • Med Center
    Carmichael, California 95608, United States
  • T. Joseph Raoof MD, Inc./Encino Research Center
    Encino, California 91436, United States
  • Neurology Center of North Orange County
    Fullerton, California 92835, United States
  • Behavioral Research Specialists, LLC
    Glendale, California 91206, United States
  • Prime Care Clinical Research
    Laguna Hills, California 92656, United States
  • Collaborative Neuroscience Network, LLC.
    Long Beach, California 90806, United States
  • Synergy San Diego
    National City, California 91950, United States
  • Newport Beach Clinical Research Associates, Inc.
    Newport Beach, California 92663, United States
  • North County Clinical Research
    Oceanside, California 92054, United States
  • Medical Center for Clinical Research
    San Diego, California 92108, United States
  • CA Medical Clinic for Headache
    Santa Monica, California 90404, United States
  • Southern California Research LLC
    Simi Valley, California 93065, United States
  • Encompass Clinical Research
    Spring Valley, California 91978, United States
  • Alpine Clinical Research Center, Inc.
    Boulder, Colorado 80301, United States
  • Colorado Springs Neurological Associates
    Colorado Springs, Colorado 80907, United States
  • Delta Waves, Inc
    Colorado Springs, Colorado 80918, United States
  • Denver Neurological Research
    Denver, Colorado 80210, United States
  • Associated Neurologists, P.C.
    Danbury, Connecticut 06810, United States
  • Associated Neurolgists of Southern Connecticut, PC
    Fairfield, Connecticut 06824, United States
  • Sarkis Clinical Trials
    Gainesville, Florida 32607, United States
  • CPI MD Clinical
    Hallandale Beach, Florida 33009, United States
  • Infinity Clinical Research, LLC
    Hollywood, Florida 33024, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • Palm Beach Neurological Center/Advanced Research Consultants, Inc.
    Palm Beach Gardens, Florida 33410, United States
  • Meridien Research
    Spring Hill, Florida 34609, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Meridien Research
    Tampa, Florida 33634, United States
  • Neurology Research Institute
    West Palm Beach, Florida 33407, United States
  • Midtown Neurology
    Atlanta, Georgia 30312, United States
  • Columbus Regional Research Institute
    Columbus, Georgia 31904, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • Great Lakes Clinical Trials
    Chicago, Illinois 60640, United States
  • Deaconess Clinic, Medical Office Building 1 Research Institute
    Newburgh, Indiana 47630, United States
  • Rowe Neurology Institute
    Lenexa, Kansas 66214, United States
  • Kansas Institute of Research
    Overland Park, Kansas 66211, United States
  • College Park Family Care Center Physicians Group - Neurology Research Department
    Overland Park, Kansas 66212, United States
  • Kentucky Pediatric/Adult Research
    Bardstown, Kentucky 40004, United States
  • Pharmasite Research, Inc.
    Baltimore, Maryland 21208, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • Northeast Medical Research Associates, Inc
    South Dartmouth, Massachusetts 02747, United States
  • MedVadis Research Corporation
    Watertown, Massachusetts 02472, United States
  • Michigan Head-Pain & Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • Beyer Research
    Kalamazoo, Michigan 49009, United States
  • Clinical Research Institute, Inc.
    Minneapolis, Minnesota 55402, United States
  • Olive Branch Family Medical Center
    Olive Branch, Mississippi 38654, United States
  • Clinvest Research, LLC
    Springfield, Missouri 65810, United States
  • Quality Clinical Research, Inc.
    Omaha, Nebraska 68114, United States
  • Clinical Research Advantage, Inc./Diagnostic Center of Medicine - Durango
    Las Vegas, Nevada 89117, United States
  • Albuquerque Clinical Trials, Inc.
    Albuquerque, New Mexico 87102, United States
  • Albuquerque Neuroscience, Inc.
    Albuquerque, New Mexico 87109, United States
  • Regional Clinical Research, Inc.
    Endwell, New York 13760, United States
  • Central New York Clinical Research
    Manlius, New York 13104, United States
  • Rochester Clinical Research, Inc.
    Rochester, New York 14609, United States
  • Neurology Associates, P.A.
    Hickory, North Carolina 28602, United States
  • Wake Research Associates, LLC
    Raleigh, North Carolina 27612, United States
  • PMG Research of Winston-Salem, LLC.
    Winston-Salem, North Carolina 27103, United States
  • Neuro-Behavioral Clinical Research, Inc.
    Canton, Ohio 44718, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • Aventiv Research, Inc
    Columbus, Ohio 43213, United States
  • Ohio Clinical Research, LLC
    Lyndhurst, Ohio 44124, United States
  • MPH IPS Research Company
    Oklahoma City, Oklahoma 73103, United States
  • NPC Research
    Oklahoma City, Oklahoma 73109, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Summit Research Network
    Portland, Oregon 97210, United States
  • Oregon Center For Clinical Investigations Inc. (OCCI, Inc.)
    Portland, Oregon 97214, United States
  • Clinical Research of Philadelphia, LLC
    Philadelphia, Pennsylvania 19114, United States
  • BTC of Lincoln
    Lincoln, Rhode Island 02865, United States
  • WR-ClinSearch, LLC
    Chattanooga, Tennessee 37421, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Clinical Neuroscience Solutions, Inc.
    Memphis, Tennessee 38119, United States
  • FutureSearch Trials of Neurology
    Austin, Texas 78731, United States
  • Tekton Research, Inc.
    Austin, Texas 78745, United States
  • FutureSearch Trials of Dallas, LP
    Dallas, Texas 75231, United States
  • Red Star Research, LLC
    Lake Jackson, Texas 77566, United States
  • Clinical Trials Texas, Inc
    San Antonio, Texas 78229, United States
  • Road Runner Research, Ltd.
    San Antonio, Texas 78249, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic Draper
    Draper, Utah 84020, United States
  • Granger Medical Clinic-Riverton
    Riverton, Utah 84065, United States
  • Optimum Clinical Research, Inc.
    Salt Lake City, Utah 84102, United States
  • Highland Clinical Research
    Salt Lake City, Utah 84124, United States
  • Tidewater Integrated Medical Research
    Virginia Beach, Virginia 23454, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • The Polyclinic Madison Center
    Seattle, Washington 98104, United States
09

References and documents

Publications

  • Johnston KM, Powell L, Popoff E, Harris L, Croop R, Coric V, L'Italien G. Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm. Clin J Pain. 2022 Nov 1;38(11):680-685. doi: 10.1097/AJP.0000000000001072. PubMed 36125279 ↗
  • Lipton RB, Singh RBH, Revicki DA, Zhao S, Shewale AR, Lateiner JE, Dodick DW. Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials. J Headache Pain. 2022 Apr 25;23(1):50. doi: 10.1186/s10194-022-01419-7. PubMed 35468729 ↗
  • Blumenfeld AM, Knievel K, Manack Adams A, Severt L, Butler M, Lai H, Dodick DW. Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials. Adv Ther. 2022 Jan;39(1):692-705. doi: 10.1007/s12325-021-01923-3. Epub 2021 Dec 7. PubMed 34874514 ↗
  • Hutchinson S, Silberstein SD, Blumenfeld AM, Lipton RB, Lu K, Yu SY, Severt L. Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II. Cephalalgia. 2021 Aug;41(9):979-990. doi: 10.1177/03331024211000311. Epub 2021 Apr 19. PubMed 33874756 ↗
  • Hutchinson S, Dodick DW, Treppendahl C, Bennett NL, Yu SY, Guo H, Trugman JM. Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials. Neurol Ther. 2021 Jun;10(1):235-249. doi: 10.1007/s40120-021-00234-7. Epub 2021 Feb 20. PubMed 33608814 ↗
  • Goadsby PJ, Blumenfeld AM, Lipton RB, Dodick DW, Kalidas K, M Adams A, Jakate A, Liu C, Szegedi A, Trugman JM. Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications. Cephalalgia. 2021 Apr;41(5):546-560. doi: 10.1177/0333102420970523. Epub 2020 Nov 26. PubMed 33241721 ↗
  • Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, Szegedi A. Ubrogepant for the Treatment of Migraine. N Engl J Med. 2019 Dec 5;381(23):2230-2241. doi: 10.1056/NEJMoa1813049. PubMed 31800988 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Dec 2017, 16 months.

Results were first posted in Jan 2019, 1 year after primary completion.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 16 months is below that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2016
First posted
Jul 11, 2016
StartActual
Jul 22, 2016
Primary completionActual
Dec 13, 2017
CompletionActual
Dec 14, 2017
Results first posted
Jan 3, 2019
Last update
Jan 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02828020
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Jul 11, 2016
Start date
Jul 22, 2016
Primary completion
Dec 13, 2017
Completion
Dec 14, 2017
Results posted
Jan 3, 2019
Last update
Jan 3, 2019

Study contacts

Adele Thorpe
study director · Allergan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ubrogepant

Start the discussion